WHO Report Raises Questions About R&D-Cost Rationale for High Cancer Drug Prices
An analysis conducted by the World Health Organization concluded that R&D costs do not provide enough evidence to justify high prices for cancer drugs.
An analysis conducted by the World Health Organization concluded that R&D costs do not provide enough evidence to justify high prices for cancer drugs.
Published interim results of ongoing clinical trials may mislead clinicians about whether a particular drug or therapy is beneficial.
Recent “right-to-try” legislation passed in the Senate could diminish the FDA’s public health mission.
Recent revisions to the Common Rule deal largely with improving transparency of informed consent while introducing a new concept of “broad consent” that can expand the reach of research.
Investigators should plan for future public health epidemics so that consensus about trial design and conduct among agencies and local communities can be reached before the next outbreak.
Meta-analyses are important aspects of medical research, but only when they are properly designed.
Evidence of the streetlight effect can be found across several fields, including medical research, where investigators draw suspect conclusions from analysis of irrelevant data.
Researchers examined the clinical development times of FDA expedited programs.
The growing acceptance of medical cannabis has been driven by clinical trials that are flawed by inadequate blinding.
Database studies may support supplemental applications for effectiveness for approved medications.